HC Wainwright Issues Positive Forecast for LifeMD Earnings

LifeMD, Inc. (NASDAQ:LFMD) – Stock analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of LifeMD in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.04) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.33 EPS.

Several other brokerages have also recently weighed in on LFMD. B. Riley Financial dropped their price target on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday. Loop Capital set a $10.00 target price on shares of LifeMD in a report on Thursday. Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a research note on Tuesday. Finally, Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, December 19th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.86.

LifeMD Stock Performance

Shares of LifeMD stock opened at $3.93 on Friday. The company’s 50 day moving average price is $3.32 and its 200-day moving average price is $4.56. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The stock has a market capitalization of $189.19 million, a price-to-earnings ratio of 15.12 and a beta of 1.92.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The company had revenue of $46.87 million during the quarter, compared to analysts’ expectations of $48.57 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after purchasing an additional 2,235 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares in the last quarter. SG Americas Securities LLC lifted its position in LifeMD by 13.8% during the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock valued at $86,000 after buying an additional 3,061 shares during the period. Invesco Ltd. lifted its position in LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after buying an additional 3,870 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of LifeMD by 8.7% during the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after buying an additional 4,281 shares in the last quarter. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.